Full year performance expected to be comfortably ahead of upgraded market consensus
Q1 2021 performance to materially exceed management expectations
EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, confirms that continued strong trading will result in the performance for the year ending 31 December 2020 being comfortably ahead of already upgraded market expectations.
Trading in the core business in the final quarter has continued to improve significantly and ongoing demand for the PrimeStore MTM COVID-19 sample collection device remained strong through to the end of the year and will continue to do so into the first quarter of 2021. Following the payment of the dividend of £4.6m in December 2020, the earlier investment of £3.8m in Trellus Health Limited, and the proceeds from the sale of Renalytix AI plc shares of £7.7m, the Company’s net cash at 31 December 2020 was in excess of £21m. The Company will pay a dividend again in December 2021 and expects to implement a progressive dividend policy.
With continued strong performance in the core business and a number of indicative orders for PrimeStore MTM for the first quarter 2021 that are likely to be realised, the Board is confident that performance for the first quarter of 2021 will be materially ahead of current management expectations, and the first quarter of 2020.
The persons responsible for arranging the release of this Announcement on behalf of the Company are Julian Baines, CEO, and Richard Evans, FD and COO respectively.
EKF Diagnostics Holdings plc
Tel: 00 44 29 2071 0570
N+1 Singer (Nomad & Broker)
Aubrey Powell / George Tzimas (Corporate Finance)
Tom Salvesen (Corporate Broking)
|Tel: 020 7496 3000|
Walbrook PR Limited
|Tel: 020 7933 8780 or
Mob: 07980 541 893 / 07584 391 303